Publications by authors named "A Ianniello"

Article Synopsis
  • Long COVID is a significant public health issue affecting many individuals, with this study aiming to identify predictors of its development and specific symptoms over time.
  • The study involved over 1,000 hospitalized COVID-19 patients in Italy, using structured phone questionnaires to assess long COVID incidence and symptoms after a median follow-up of 19 months.
  • Results indicated that 91.7% experienced long COVID, particularly affecting respiratory and neurological systems, with vaccination reducing symptom odds and Delta variant infection greatly increasing the risk for neuropsychiatric symptoms.
View Article and Find Full Text PDF

Background: Fatigue, depression and slow processing speed are debilitating symptoms in people with Relapsing-Remitting Multiple Sclerosis (RRMS) that significantly impacts on the quality of life. Natalizumab, a disease-modifying treatment, improves clinical symptoms but questions remain about the comparative efficacy between its standard interval dosing (SID) and extended interval dosing (EID) schedules.

Objective: To examine the impact of short term natalizumab dosing schedules-SID versus EID-on the so called "invisible symptoms", specifically focusing on symptom exacerbation during the 'wearing-off' phase before infusion and the subsequent relief post-infusion.

View Article and Find Full Text PDF

Background: Upadacitinib (UPA) is a selective, reversible Janus kinase inhibitor (JAKi) approved for the treatment of RA. However, there is still no solid evidence on the long-term efficacy of UPA in treated patients. The purpose of this study was to determine the efficacy of UPA to obtain remission or low disease activity (LDA) in a series of UPA patients in patients with RA after 6 and 12 months of treatment in a real-world setting.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effects of discontinuing dimethyl fumarate (DMF) during early pregnancy in women with multiple sclerosis (MS), analyzing 137 pregnancies from Italian MS Centers.
  • Results show that disease activity typically decreases during pregnancy but increases postpartum; higher relapse rates before conception correlate with faster relapses after giving birth.
  • Importantly, DMF exposure during early pregnancy did not negatively affect fetal outcomes, suggesting it is safe for the pregnancy context.
View Article and Find Full Text PDF

Background: Pediatric-onset Multiple Sclerosis (POMS) patients show more inflammatory disease compared with adult-onset MS. However, highly effective treatments are limited with only fingolimod being approved in Italy and natalizumab prescribed as off-label treatment.

Objectives: to compare the efficacy of natalizumab versus fingolimod in POMS.

View Article and Find Full Text PDF